

Antiparasitic Compounds Licensing Opportunity



Technology Brief

Professor Andy Thompson, in collaboration with Dr Wayne Best of Epichem Pty Ltd., has developed novel anti-parasitic compounds with efficacy against *Trypanosoma*, *Leishmania donovani*, *Echinococcus*, *Cryptosporidium*, *Giardia* and *Plasmodium*. The Murdoch team has synthesised more than 250 compounds using rational drug design, and has successfully identified candidates with strong efficacy data in vitro. The research is supported by a grant from the Drugs for Neglected Disease Initiative, and is currently in pre-clinical development.

Murdoch University is seeking partners to develop the compounds for application in the human and animal health pharmaceutical sector. In particular, Murdoch is seeking to license its novel compounds for use in the following sectors:

- Human Health: Cryptosporidiosis and Giardiasis,
- Companion Animal Health: Neosporosis, Nagana and Surra,
- Livestock Animal Health: Neosporosis, Nagana and Surra.

Contact Details

Dr Patty Washer, Director of Commercialisation
P.washer@murdoch.edu.au
+61 (8) 9360 2633